The Role of Cardio-Oncology in the Interprofessional Care of Adult Patients Receiving Cancer Therapy

Miller, 2016, Cancer treatment and survivorship statistics, 2016, CA Cancer J Clin, 66, 271, 10.3322/caac.21349 de Moor, 2013, Cancer survivors in the united states: prevalence across the survivorship trajectory and implications for care, Cancer Epidemiol Biomarkers Prev, 22, 561, 10.1158/1055-9965.EPI-12-1356 Wells, 2010, Reversibility of left ventricular dysfunction resulting from chemotherapy: can this be expected?, Prog Cardiovasc Dis, 53, 140, 10.1016/j.pcad.2010.06.005 Hanrahan, 2007, Overall survival and cause-specific mortality of patients with stage T1a, bN0M0 breast carcinoma, J Clin Oncol, 25, 4952, 10.1200/JCO.2006.08.0499 Chu, 2007, Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib, Lancet, 370, 2011, 10.1016/S0140-6736(07)61865-0 Force, 2008, Cardiotoxicity of the new cancer therapeutics – mechanisms of, and approaches to, the problem, Drug Discov Today, 13, 778, 10.1016/j.drudis.2008.05.011 Janjan, 2008, Pain and suffering during cancer therapy: continued sins of omission, Int J Radiat Oncol Biol Phys, 72, 6, 10.1016/j.ijrobp.2008.05.048 Fromme, 2004, How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the quality-of-life questionnaire c30, J Clin Oncol, 22, 3485, 10.1200/JCO.2004.03.025 Wilson, 1998, Prediction of coronary heart disease using risk factor categories, Circulation, 97, 1837, 10.1161/01.CIR.97.18.1837 Lenihan, 2008, Multidisciplinary strategy for managing cardiovascular risks when treating patients with early breast cancer, Oncologist, 13, 1224, 10.1634/theoncologist.2008-0112 Plana, 2014, Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging, Eur Heart J Cardiovasc Imaging, 15, 1063, 10.1093/ehjci/jeu192 Truong, 2014, Chemotherapy-induced cardiotoxicity: detection, prevention, and management, Can J Cardiol, 30, 869, 10.1016/j.cjca.2014.04.029 Limat, 2003, Early cardiotoxicity of the chop regimen in aggressive non-hodgkin's lymphoma, Ann Oncol, 14, 277, 10.1093/annonc/mdg070 Hequet, 2004, Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults, J Clin Oncol, 22, 1864, 10.1200/JCO.2004.06.033 Jones, 2007, Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab, Cancer Epidemiol Biomarkers Prev, 16, 1026, 10.1158/1055-9965.EPI-06-0870 Jones, 2007, Cardiovascular reserve and risk profile of postmenopausal women after chemoendocrine therapy for hormone receptor positive operable breast cancer, Oncologist, 12, 1156, 10.1634/theoncologist.12-10-1156 Lotrionte, 2013, Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity, Am J Cardiol, 112, 1980, 10.1016/j.amjcard.2013.08.026 Steinherz, 1991, Cardiac toxicity 4 to 20 years after completing anthracycline therapy, JAMA, 266, 1672, 10.1001/jama.1991.03470120074036 1995, Effects of radiotherapy and surgery in early breast cancer: an overview of the randomized trials, N Engl J Med, 333, 1444, 10.1056/NEJM199511303332202 Bouchardy, 2010, Excess of cardiovascular mortality among node-negative breast cancer patients irradiated for inner-quadrant tumors, Ann Oncol, 21, 459, 10.1093/annonc/mdp341 McGale, 2011, Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden, Radiother Oncol, 100, 167, 10.1016/j.radonc.2011.06.016 Xu, 2013, Dosimetric evaluation and treatment outcome of intensity modulated radiation therapy after doxorubicin-based chemotherapy for primary mediastinal large b-cell lymphoma, Int J Radiat Oncol Biol Phys, 85, 1289, 10.1016/j.ijrobp.2012.10.037 Pugh, 2010, Cardiac mortality in patients with stage I and II diffuse large B-cell lymphoma treated with and without radiation: a surveillance, epidemiology, and end-results analysis, Int J Radiat Oncol Biol Phys, 76, 845, 10.1016/j.ijrobp.2009.02.045 Darby, 2013, Ischemic heart disease after breast cancer radiotherapy, N Engl J Med, 368, 2527, 10.1056/NEJMoa1209825 Cutter, 2015, Risk of valvular heart disease after treatment for hodgkin lymphoma, J Natl Cancer Inst, 107, 10.1093/jnci/djv008 Darby, 2010, Radiation-related heart disease: current knowledge and future prospects, Int J Radiat Oncol Biol Phys, 76, 656, 10.1016/j.ijrobp.2009.09.064 Darby, 2013, Risk of ischemic heart disease in women after radiotherapy for breast cancer, N Engl J Med, 368, 987, 10.1056/NEJMoa1209825 Vogel, 2002, Efficacy and safety of trastuzumab as a single agent in first-line treatment of her2-overexpressing metastatic breast cancer, J Clin Oncol, 20, 719, 10.1200/JCO.2002.20.3.719 Slamon, 2011, Adjuvant trastuzumab in HER2-positive breast cancer, N Engl J Med, 365, 1273, 10.1056/NEJMoa0910383 Dy, 2013, Understanding, recognizing, and managing toxicities of targeted anticancer therapies, CA Cancer J Clin, 63, 249, 10.3322/caac.21184 Bair, 2013, Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives, Trends Cardiovasc Med, 23, 104, 10.1016/j.tcm.2012.09.008 Thompson, 2016, Atrial fibrillation in cll patients treated with ibrutinib. An international retrospective study, Br J Haematol, 175, 462, 10.1111/bjh.14324 Moja, 2012, Trastuzumab containing regimens for early breast cancer, Cochrane Database Syst Rev, 10.1002/14651858.CD006243.pub2 Bowles, 2012, Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study, J Natl Cancer Inst, 104, 1293, 10.1093/jnci/djs317 Ewer, 2005, Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment, J Clin Oncol, 23, 7820, 10.1200/JCO.2005.13.300 Wadhwa, 2009, Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study, Breast Cancer Res Treat, 117, 357, 10.1007/s10549-008-0260-6 Cardinale, 2010, Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy, J Am Coll Cardiol, 55, 213, 10.1016/j.jacc.2009.03.095 Parent, 2016, The cardio-oncology program: a multidisciplinary approach to the care of cancer patients with cardiovascular disease, Can J Cardiol, 32, 847, 10.1016/j.cjca.2016.04.014 Armenian, 2017, Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline, J Clin Oncol, 35, 893, 10.1200/JCO.2016.70.5400 Abdel-Qadir, 2016, Prevention, detection, and management of chemotherapy-related cardiac dysfunction, Can J Cardiol, 32, 891, 10.1016/j.cjca.2016.01.028 Pituskin, 2017, Multidisciplinary approach to novel therapies in cardio-oncology research (manticore 101-breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity, J Clin Oncol, 35, 870, 10.1200/JCO.2016.68.7830 Chow, 2011, Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation, Ann Intern Med, 155, 21, 10.7326/0003-4819-155-1-201107050-00004 Pituskin, 2016, Cardio-oncology interventions in outpatients referred for autologous bone marrow transplantation, J Clin Oncol, 34, 137, 10.1200/jco.2016.34.3_suppl.137 Bosch, 2013, J Am Coll Cardiol, 61, 2355, 10.1016/j.jacc.2013.02.072 Sulpher, 2015, An international survey of health care providers involved in the management of cancer patients exposed to cardiotoxic therapy, J Oncol, 2015, 391848, 10.1155/2015/391848 Marwick, 2016, Cancer therapy-related cardiac dysfunction: unresolved issues, Can J Cardiol, 32, 842, 10.1016/j.cjca.2016.05.001 Bultz, 2011, Implementing screening for distress, the 6th vital sign: a Canadian strategy for changing practice, Psychooncology, 20, 463, 10.1002/pon.1932 Waller, 2012, Using screening for distress, the sixth vital sign, to advance patient care with assessment and targeted interventions, Support Care Cancer, 20, 2241, 10.1007/s00520-012-1506-8 Watson, 2016, Evaluating the impact of provincial implementation of screening for distress on quality of life, symptom reports, and psychosocial well-being in patients with cancer, J Natl Compr Canc Netw, 14, 164, 10.6004/jnccn.2016.0019 Denlinger, 2016, NCCN guidelines insights: survivorship. Version 1.2016, J Natl Compr Canc Netw, 14, 715, 10.6004/jnccn.2016.0073 Balady, 2011, Referral, enrollment, and delivery of cardiac rehabilitation/secondary prevention programs at clinical centers and beyond: a presidential advisory from the American Heart Association, Circulation, 124, 2951, 10.1161/CIR.0b013e31823b21e2 Pituskin, 2016, Rationale and design of the multidisciplinary team intervention in cardio-oncology study (Titan), BMC Cancer, 16, 733, 10.1186/s12885-016-2761-8 Pituskin, 2016, Feasibility and acceptability of integrated cardiac rehabilitation in outpatients referred for autologous bone marrow transplantation, J Clin Oncol, 34, 139, 10.1200/jco.2016.34.3_suppl.139